CLAIMS

1. A compound of Formula (IV):



(IV),

or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:

ring A is a 5-membered fused heteroaryl ring having from 1-3 heteroatoms as ring members selected from O, N or S;

each R^7 is independently selected from C_{1-6}alkyl, deuterated C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl, C_{2-6}alkynyl, -X^1-aryl, aryl-C_{1-4}alkylene-X^1-, heteroaryl-X^1-, heteroaryl-C_{1-4} alkylene-X^1-, C_{3-6}cycloalkyl-X^1-, C_{3-6}cycloalkyl-C_{1-4}alkylene-X^1-, C_{3-6}cycloalkenyl-X^1-, CH_2=CH-X^1, C_{3-6}cycloalkyl-C_{2-4}alkenylene-X^1-, C_{3-6}cycloalkyl-C_{2-4}alkynylene-X^1-, heterocyclyl-X^1-, heterocyclyl-C_{1-4}alkylene-X^1- or R^8, wherein R^8 is selected from halogen, -CN, -OH, -NH_2, -NO_2, -C(O)OH, -C(S)OH, -C(O)NH_2, -C(S)NH_2, -S(O)$_2NH_2$, -NHC(O)NH_2, -NHC(S)NH_2, -NHS(O)$_2NH_2$, -C(NH)NH_2, -OR^a, -SR^a, -OC(O)R^a, -OC(S)R^a,-C(O)R^a, -C(S)R^a, -C(S)OR^a, -S(O)R^a, -S(O)$_2R^a$, -C(O)NHR^a, -C(S)NHR^a, -C(O)NR^aR^a, -C(S)NR^aR^a, -S(O)$_2$NHR^a, -S(O)$_2$NR^aR^a, -C(NH)NHR^a, -C(NH)NR^aR^a, -NHC(O)R^a, -NHC(S)R^a, -NR^aC(O)R^a, -NR^aC(S)R^a, -NHS(O)$_2R^a$, -NR^aS(O)$_2R^a$, -NHC(O)NHR^a, -NHC(S)NHR^a, -NR^aC(O)NH_2, -NR^aC(S)NH_2, -NR^aC(O)NHR^a, -NR^aC(S)NHR^a, -NHC(O)NR^aR^a, -NHC(S)NR^aR^a, -NR^aC(O)NR^aR^a, -NR^aC(S)NR^aR^a, -NHS(O)$_2$NHR^a, -NR^aS(O)$_2NH_2$, -NR^aS(O)$_2$NHR^a, -NHS(O)$_2$NR^aR^a, -NR^aS(O)$_2$NR^aR^a, -NHR^a or -NR^aR^a, wherein each R^a is independently selected from C_{1-6}alkyl, aryl, aryl-C_{1-2}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4}alkyl, heterocycloalkyl or heterocycloalkyl-C_{1-4}alkyl, wherein each R^a is further optionally substituted with 1-3 R^b substituents independently selected from C_{1-6}alkyl, C_{1-6}alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy; wherein X^1 is a bond or –C(O)- and

wherein R^7 is optionally substituted with from 1-5 R^9 members selected from halogen,

-CH=CH_2, -CN, -OH, -NH_2, -NO_2, -C(O)OH, -C(S)OH, -$C(O)NH_2$, -$C(S)NH_2$, -$S(O)_2NH_2$, -$NHC(O)NH_2$, -$NHC(S)NH_2$, -$NHS(O)_2NH_2$, -$C(NH)NH_2$, -OR^c, -SR^c, -$OC(O)R^c$, -$OC(S)R^c$, -$P(=O)HR^c$, -$P(=O)R^cR^c$, -$PH(=O)OR^c$, -$P(=O)(OR^c)_2$, -$OP(=O)(OR^c)_2$, -$C(O)R^c$, -$C(S)R^c$, -$C(O)OR^c$, -$C(S)OR^c$, -$S(O)R^c$, -$S(O)_2R^c$, -$C(O)NHR^c$, -$C(S)NHR^c$, -$C(O)NR^cR^c$, -$C(S)NR^cR^c$, -$S(O)_2NHR^c$, -$S(O)_2NR^cR^c$, -$C(NH)NHR^c$, -$C(NH)NR^cR^c$, -$NHC(O)R^c$, -$NHC(S)R^c$, -$NR^cC(O)R^c$, -$NR^cC(S)R^c$, -$NHS(O)_2R^c$, -$NR^cS(O)_2R^c$, -$NHC(O)NHR^c$, -$NHC(S)NHR^c$, -$NR^cC(O)NH_2$, -$NR^cC(S)NH_2$, -$NR^cC(O)NHR^c$, -$NR^cC(S)NHR^c$, -$NHC(O)NR^cR^c$, -$NHC(S)NR^cR^c$, -$NR^cC(O)NR^cR^c$, -$NR^cC(S)NR^cR^c$, -$NHS(O)_2NHR^c$, -$NR^cS(O)_2NH_2$, -$NR^cS(O)_2NHR^c$, -$NHS(O)_2NR^cR^c$, -$NR^cS(O)_2NR^cR^c$, -NHR^c, R^c or -NR^cR^c; or two adjacent R^9 substituents, together with the atoms to which they are attached, form a 5 or 6-membered ring having from 0-2 heteroatoms selected from O, N or S;

wherein each R^c is independently selected from C_{1-6}alkyl, aryl, aryl-C_{1-2}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4}alkyl, heterocycloalkyl or heterocycloalkyl-C_{1-4}alkyl, wherein each R^c is further optionally substituted with from 1-3 R^d groups independently selected from -CN, -OH, -$N(R^e)(R^e)$, -NO_2, -C(O)OH, - $C(O)NH_2$, -$S(O)_2NH_2$, -$NHC(O)NH_2$, -$C(NH)NH_2$, -$OC(O)R^e$, -$OC(S)R^e$, -$C(O)R^e$, -$C(S)R^e$, -$C(O)OR^e$, -$P(=O)HR^e$, -$P(=O)R^eR^e$, -$PH(=O)OR^e$, -$P(=O)(OR^e)_2$, -$OP(=O)(OR^e)_2$, -$S(O)_2R^e$, -$C(O)NHR^e$, C_{1-6}alkyl, C_{1-6}alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy, wherein each R^e is independently C_{1-6}alkyl;

or two adjacent R^7 substituents together with the atoms to which they are attached form a 4-, 5- or 6-membered carbocyclic ring or heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S;

Y^2 is C-R^{10}, wherein R^{10} is H, C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl, C_{2-6}alkynyl, aryl-C_{1-4}alkyl-, heteroaryl-C_{1-4} alkyl-, C_{3-6}cycloalkyl-C_{1-4}alkyl-, C_{3-6}cycloalkenyl-C_{1-4}alkyl-, CH_2=CH-X^2-, C_{3-6}cycloalkyl-C_{2-4}alkenylene-X^2-, C_{3-6}cycloalkyl-C_{2-4}alkynylene-X^2-, heterocyclyl-C_{1-4}alkyl- or R^8, each of which is optionally substituted with from 1-5 R^9 groups; wherein X^2 is C_{1-4}alkylene, -O-, -S- or -NH-;

R^3 and R^4 are each independently selected from H, halogen, C_{1-6} alkyl, C_{1-4}haloalkyl, C_{1-4}haloalkoxy, cyclopropyl, phenyl, -CN, CN-CH_2-, C_{1-6}alkoxy, or R^g; or R^3 and R^4 are taken together with the atoms to which they are attached form an optionally substituted 4 to 8-membered ring having from 0-2 heteroatoms as ring members selected from O, N or S;

wherein R^g is -OH, -NH_2, -NO_2, -C(O)OH, -C(S)OH, -$C(O)NH_2$, -$C(S)NH_2$, -$S(O)_2NH_2$, -$NHC(O)NH_2$, -$NHC(S)NH_2$, -$NHS(O)_2NH_2$, -$C(NH)NH_2$, -OR^h, -SR^h, -$OC(O)R^h$, -$OC(S)R^h$, -$C(O)R^h$, -$C(S)R^h$, -$C(O)OR^h$, -$C(S)OR^h$, -$S(O)R^h$, -$S(O)_2R^h$, -$C(O)NHR^h$, -$C(S)NHR^h$, -$C(O)NR^hR^h$, -$C(S)NR^hR^h$, -$S(O)_2NHR^h$, -$S(O)_2NR^hR^h$, -$C(NH)NHR^h$, -$C(NH)NR^hR^h$, -$NHC(O)R^h$, -$NHC(S)R^h$, -$NR^hC(O)R^h$, -$NR^hC(S)R^h$, -$NHS(O)_2R^h$, -$NR^hS(O)_2R^h$, -$NHC(O)NHR^h$, -$NHC(S)NHR^h$, -$NR^hC(O)NH_2$, -$NR^hC(S)NH_2$, -$NR^hC(O)NHR^h$, -$NR^hC(S)NHR^h$, -$NHC(O)NR^hR^h$, -$NHC(S)NR^hR^h$, -$NR^hC(O)NR^hR^h$, -$NR^hC(S)NR^hR^h$, -$NHS(O)_2NHR^h$, -$NR^hS(O)_2NH_2$, -$NR^hS(O)_2NHR^h$, -$NHS(O)_2NR^hR^h$, -$NR^hS(O)_2NR^hR^h$, -NHR^h or -NR^hR^h, wherein each R^h is independently H or $C_{1\text{-}2}$alkyl;

R^5 is H or $C_{1\text{-}4}$alkyl;

Y^1 is N or C;

Y^3 is CH; and

the subscript m is 0, 1 or 2.

2. The compound of claim **1**, having Formulas (IVa), (IVb), (IVc), or (IVd):



(IVa)



(IVb)



(IVc)

or



(IVd)

3. The compound of claim **1**, having Formula (IVa-2):



(IVa-2).

4. The compound of claim **3**, wherein R^{10} is H.

5. The compound of claim **3**, wherein R^3 and R^4 are each independently H, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, cyclopropyl, -CN, C_{1-4}haloalkyl or C_{1-4}haloalkoxy; or R^3 and R^4 are taken together with the atoms to which they are attached form an optionally substituted fused 4 to 8-membered ring having from 0-2 heteroatoms selected from N or S.

6. The compound of claim **3**, wherein R^3 and R^4 are each independently selected from H, Br, Cl, methyl, ethyl, cyclopropyl, -CN, CF_3, CHF_2, CH_2F, $-OCH_3$, $-OCF_3$, $-OCHF_2$ or $-OCH_2F$, $CNCH_2$-, $NH_2C(O)$-, CH_3NHCO- or $CH_3C(O)NH$-; or R^3 and R^4 are taken together with the atoms to which they are attached form a fused ring selected from benzene, pyridine, pyrimidine, pyrazine, pyridazine, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cyclooctane or cyclooctatriene, each of which is optionally substituted.

7. The compound of claim **3**, wherein R^7 is selected from halogen, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl-C_{1-4}alkyl, aryl, aryl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4} alkyl, heterocyclyl or heterocyclyl-C_{1-4}alkyl, $-C(O)-R^a$, $-C(O)NHR^a$, $-C(O)NR^aR^a$, $-NHC(O)R^a$, $-NHC(O)NHR^a$, $-NHC(O)NR^aR^a$, $-NR^aR^a$, $-NHR^a$, $-OC(O)R^a$, $-SO_2R^a$, $-NHSO_2R^a$, $-NHSO_2NHR^a$, $-NHSO_2NR^aR^a$, $-SO_2NHR^a$ or $-SO_2NR^aR^a$, wherein at each occurrence R^7 is optionally substituted with from 1-4 R^9 members, wherein each R^9 is independently selected from halogen, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6}cycloalkyl, C_{3-6} cycloalkyl-C_{1-4}alkyl, aryl, aryl-C_{1-2}alkyl, heteroaryl, heteroaryl-C_{1-4} alkyl, heterocyclyl or heterocyclyl-C_{1-4}alkyl or the two adjacent R^9 substituents on an aromatic ring are taken together to form a 5 or 6-membered ring having from 0-2 heteroatoms selected from O, N or S.

8. The compound of claim **3**, wherein R^7 is vinyl, ethynyl, deuterated C_{1-6}alkyl, C_{1-6}alkyl, halogen, C_{1-6}alkoxy, 2-cyclopropylethynyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, benzyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiozolyl, 4-thiozolyl, 5-thiozolyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, cyclopropyl, cyclopropylmethyl, cyclopropylcarbonyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl,

cyclohexylmethyl, benzoyl, phenylcarbamoyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-piperazinyl, 2-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-cyclopentenyl, 1-cyclohexenyl, 1,2,3,6-tetrahydropyridin-4-yl, 1,2,3,6-tetrahydropyridin-5-yl, 2,5-dihydro-1H-pyrrol-3-yl, 2,5-dihydro-pyrrol-1-yl, 2,3-dihydro-1,4-benzodioxin-5-yl, 1,3-benzodioxol-4-yl, 1,3-benzodioxol-5-yl, indan-1-yl, indan-2-yl, 1,2-benzoxazolyl, 1,3-benzoxazolyl, each of which is optionally substituted with from 1-4 R^9 members.

9. The compound of claim **3**, wherein R^7 is selected from Cl, Br, phenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 1-cyclopropylcarbonyl-1,2,3,6-tetrahydropyridin-4-yl, 1-morpholinocarbonyl, 1,2,3,6-tetrahydropyridin-4-yl, 1,2,3,6-tetrahydropyridin-5-yl, 1,3-dimethyl-pyrazol-4-yl or 1-(4-piperidinyl)pyrazol-4-yl, 3,4-dimethyl-1H-pyrazol-5-yl, 1-(cyclopropylcarbonyl)-2,5-dihydro-pyrrol-3-yl, 3-fluoro-propynyl, 3,5-dimethyl-isoxazol-4-yl, 5-thiazolyl, each of which is optionally substituted with from 1-3 substituents independently selected from F, Cl, $-CH_3$, ethyl, propyl, isopropyl, 2-methylpropyl, CD_3, $-OCH_3$, CN, CH_2F, $-CF_2H$, CF_3, CF_3O-, CHF_2O-, CH_2FO-, NH_2, $-N(CH_3)_2$, $-NHCH_3$, CH_3CONH-, $NH_2C(O)-$, $CH_3NHC(O)-$, $(CH_3)_2NC(O)-$, cyclopropyl, 1-cyanocyclopropyl, 4-morpholinyl, 4-morpholinylmethyl, 4-thiomorpholinyl, 4-morpholinylcarbonyl, 4-thiomorpholinylcarbonyl, 4-morpholinylmethylcarbonyl, 4-thiomorpholinylmethylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, $-PH(=O)(C_{1-4}alkyl)$, $-P(=O)(C_{1-4}alkyl)_2$, $-PH(=O)(OC_{1-4}alkyl)$, $-P(=O)(OC_{1-4}alkyl)_2$, $-OP(=O)(OC_{1-4}alkyl)_2$, 4-piperidinyl, 4-piperidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperazinylcarbonyl, t-butoxycarbonyl, 2-(4-morpholinyl)-ethyl, 2-(4-morpholinyl)-ethoxy, 1,2-dihydroxyethylcarbonyl, 3-methoxypropoxy, 1-pyrrolidinyl, phenyl-SO_2NH-, $C_{1-4}alkyl-SO_2NH-$, cyclopropyl-SO_2NH-, p-$CH_3C_6H_4SO_2NH-$, NH_2SO_2-, $C_{1-4}alkyl-NHSO_2-$, $(C_{1-4}alkyl)_2NSO_2-$, $C_{1-4}alkyl-NHC(O)-$, $C_{1-4}alkyl-C(O)-$, $C_{1-4}alkyl-SO_2-$, 4-morpholinyl-$C_{1-4}alkoxy$, or 1-pyrrolidinylcarbonyl.

10. The compound of claim **1**, wherein: Y^1 is C.

11. The compound of claim **3**, wherein R^5 is H.

12. A pharmaceutical composition comprising a compound of claim **3** and a pharmaceutically acceptable carrier or excipient.

13. A pharmaceutical composition comprising a compound of claim **3** and another therapeutic agent.

14. A compound selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

, and

,

or a pharmaceutically acceptable salt thereof.

15. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

16. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

17. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

18. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

19. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

20. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.